Shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) fell 3.5% during mid-day trading on Friday . The stock traded as low as $15.37 and last traded at $15.67, with a volume of 101,414 shares changing hands. The stock had previously closed at $16.24.

ADMS has been the subject of several recent analyst reports. Mizuho raised their target price on Adamas Pharmaceuticals from $14.00 to $17.00 and gave the company a “neutral” rating in a research note on Thursday, April 28th. Noble Financial initiated coverage on Adamas Pharmaceuticals in a research note on Friday, June 17th. They set a “buy” rating and a $25.00 target price for the company. Credit Suisse Group AG restated a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Wednesday, June 22nd. JMP Securities restated a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Wednesday, June 15th. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $44.00 target price on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $33.60.

The firm’s market cap is $335.43 million. The stock has a 50-day moving average price of $16.06 and a 200 day moving average price of $16.46.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.11. Equities analysts expect that Adamas Pharmaceuticals Inc. will post ($3.09) EPS for the current fiscal year.

An institutional investor recently raised its position in Adamas Pharmaceuticals stock. Dimensional Fund Advisors LP raised its stake in shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) by 585.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 69,411 shares of the specialty pharmaceutical company’s stock after buying an additional 59,285 shares during the period. Dimensional Fund Advisors LP owned about 0.38% of Adamas Pharmaceuticals worth $1,966,000 as of its most recent filing with the SEC.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.